Literature DB >> 20590832

The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease.

Kazuma Murakami1, Yuichi Masuda, Takuji Shirasawa, Takahiko Shimizu, Kazuhiro Irie.   

Abstract

One hallmark of Alzheimer's disease (AD) is the accumulation of amyloid beta (Abeta) peptides in the brain; Abeta mainly consists of 42-mer and 40-mer peptides (Abeta42 and Abeta40). Abeta42 plays a more critical role in the pathogenesis of AD because Abeta42 aggregates much faster and is more toxic than Abeta40. Therefore, there is an urgent need to elucidate the mechanism of aggregation and neurotoxicity of Abeta42 to develop therapeutic agents. Here, we introduce the pathological role of Abeta42 in AD and review our recent findings of the structural analysis of Abeta42 using systematic proline replacement, electron spin resonance and solid-state nuclear magnetic resonance, and the new mechanism of neurotoxicity of Abeta42 through the formation of radicals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590832     DOI: 10.1111/j.1447-0594.2010.00598.x

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  10 in total

1.  Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces.

Authors:  Elizabeth A Yates; Elena M Cucco; Justin Legleiter
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

2.  Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.

Authors:  D P Devanand; N Schupf; Y Stern; R Parsey; G H Pelton; P Mehta; R Mayeux
Journal:  Neurology       Date:  2011-06-29       Impact factor: 9.910

3.  The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation.

Authors:  Iryna Benilova; Rodrigo Gallardo; Andreea-Alexandra Ungureanu; Virginia Castillo Cano; An Snellinx; Meine Ramakers; Carmen Bartic; Frederic Rousseau; Joost Schymkowitz; Bart De Strooper
Journal:  J Biol Chem       Date:  2014-09-24       Impact factor: 5.157

4.  Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Aβ42.

Authors:  Naotaka Izuo; Toshiaki Kume; Mizuho Sato; Kazuma Murakami; Kazuhiro Irie; Yasuhiko Izumi; Akinori Akaike
Journal:  ACS Chem Neurosci       Date:  2012-06-06       Impact factor: 4.418

5.  Macrocyclic Peptides Derived from Familial Alzheimer's Disease Mutants Show Charge-Dependent Oligomeric Assembly and Toxicity.

Authors:  William J Howitz; Gretchen Guaglianone; Kate J McKnelly; Katelyn Haduong; Shareen N Ashby; Mohamed Laayouni; James S Nowick
Journal:  ACS Chem Neurosci       Date:  2022-02-22       Impact factor: 5.780

6.  Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation.

Authors:  L Kulic; J McAfoose; T Welt; C Tackenberg; C Späni; F Wirth; V Finder; U Konietzko; M Giese; A Eckert; K Noriaki; T Shimizu; K Murakami; K Irie; S Rasool; C Glabe; C Hock; R M Nitsch
Journal:  Transl Psychiatry       Date:  2012-11-13       Impact factor: 6.222

7.  E22Δ Mutation in Amyloid β-Protein Promotes β-Sheet Transformation, Radical Production, and Synaptotoxicity, But Not Neurotoxicity.

Authors:  Takayuki Suzuki; Kazuma Murakami; Naotaka Izuo; Toshiaki Kume; Akinori Akaike; Tetsu Nagata; Tomoyuki Nishizaki; Takami Tomiyama; Hiroshi Takuma; Hiroshi Mori; Kazuhiro Irie
Journal:  Int J Alzheimers Dis       Date:  2010-12-19

8.  Formation of the 42-mer Amyloid β Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease.

Authors:  Kazuma Murakami; Takahiko Shimizu; Kazuhiro Irie
Journal:  J Amino Acids       Date:  2011-01-16

9.  Apple Procyanidins Suppress Amyloid β-Protein Aggregation.

Authors:  Toshihiko Toda; Tadahiro Sunagawa; Tomomasa Kanda; Motoyuki Tagashira; Takuji Shirasawa; Takahiko Shimizu
Journal:  Biochem Res Int       Date:  2011-08-02

10.  A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease.

Authors:  Naotaka Izuo; Chihiro Kasahara; Kazuma Murakami; Toshiaki Kume; Masahiro Maeda; Kazuhiro Irie; Koutaro Yokote; Takahiko Shimizu
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.